M ost peripheral tissue cells express major histocompatibility complex (MHC) class I (but not class II or costimulator) molecules, and almost all tissue cells can present antigenic peptides (eg, after infection) and thereby become a focus for specific CD8 T-cell recognition. It is unresolved which nonprofessional (parenchymal, endothelial, epithelial) antigen-presenting cell (APC) can locally prime naive CD8 T cells, which costimulatory and coinhibitory molecules of the tumor necrosis factor (TNF) 1 and B7 2 superfamilies are involved in modulating such responses, and how responses primed by nonprofessional APC differ from those primed by professional APC.
The liver plays diverse roles in T-cell immunity such as inducing and maintaining tolerance, regulating T-cell homeostasis, and supporting intrahepatic T-cell responses to hepatotropic pathogens. 3 T cells enter the liver through sinusoids lined by endothelial cells. These have large fenestrae that establish continuity between the sinusoidal lumen and the perisinusoidal space (of Disse), a narrow gap between the antiluminal surface of the endothelia and the hepatocyte (HC). T cells have direct access to the HC surface that is substantially enlarged by numerous microvilli. T cells directly contact HC either in the sinusoids through HC microvilli that project through endothelial fenestrae or after migration through the endothelial barrier into the perisinusoidal space. MHC class I transcript levels and surface display by murine HC are nearly as high as on splenocytes. 4, 5 HC that express a relevant antigen retain naive CD8 T cells within minutes after adoptive transfer in the liver where they are activated in situ as soon as 2 hours post-transfer. 6 HCprimed CD8 T cells already leave the liver 24 hours post-transfer after undergoing only limited local cell division. HC can prime specific activation and proliferation of naive CD8 T cells in vitro. 6 This may result from a strong signal delivered to the T-cell receptor (TCR) by its authentic ligand that requires no costimulation for proliferation and differentiation. 7 Alternatively, this response may be costimulated by HC-derived signals that remain to be identified.
Five members of the B7 family (ICOS ligand, B7-H1/PD-L1, B7-DC/PD-L2, B7-H3, B7-H4/B7x/B7S1) expressed by professional and/or nonprofessional APC have been recently described. 8 Binding of these molecules to CD28 family members (ICOS, PD-1) or the B7 family member CD80 9 expressed by T cells delivers activating and/or inhibitory signals that fine-tune T-cell responses. PD-1-mediated signals down modulate proliferation and interferon (IFN)-␥ production of activated autoreactive, 10, 11 alloreactive, 12, 13 tumor-reactive, 14 or fetus-reactive 15 T cells. Studies using genetically deficient B7-H1 Ϫ/Ϫ APC or antibody-mediated B7-H1 blockade support the notion that this B7-like molecule down-regulates T-cell responses and hence qualifies as a "coinhibitor." 2 In the liver, B7-H1 is expressed by sinusoidal endothelial cells, Kupffer cells, and HC. 16 -18 CD8 (but not CD4) T cells spontaneously accumulate in the liver of B7-H1 Ϫ/Ϫ mice because of impaired apoptotic elimination, indicating that B7-H1 regulates deletion of CD8 T blasts in the liver. 19 We investigated whether B7-H1 expressed on the surface of HC regulates specific priming and/or specific recall of H-2 class I-restricted CD8 T-cell responses.
Materials and Methods Mice
H-2 b C57BL/6J (B6) mice, B7-H1 Ϫ/Ϫ B6 mice, 19 TCR transgenic OT-I B6 mice, and RAG1 Ϫ/Ϫ OT-I B6 mice were bred and kept under standard pathogen-free conditions in the animal colony of Ulm University (Ulm, Germany). Female mice were used at 8 -12 weeks of age. All animal experiments were performed according to the guidelines of the local Animal Use and Care Committee and the National Animal Welfare Law.
Isolation of HC
HC were isolated as described. 20, 21 The liver was perfused and digested in vivo, removed, and gently pressed through a mesh. Parenchymal cells were separated from nonparenchymal cells by centrifugation (50g, 5 minutes). HC were washed, and scatter-gated HC were purged by FACSAria sorting (Becton and Dickinson, Mountain View, CA) of contaminating dendritic cells (DC) (MHC-II, B220, CD11c), macrophages (CD11b), T cells (CD3), B cells (CD19), and natural killer (NK) cells (DX5). The purity of the isolated HC was Ͼ99% as verified cytologically. Sorter-purified HC were washed and resuspended in medium supplemented with 5% vol/vol fetal calf serum (catalogue No. 10270-106; Life Technologies).
Isolation of Splenic DC and OT-I CD8 T Cells
B cells, NK cells, and T cells were depleted by magnetic bead-activated cell sorting (MACS) from single spleen cell suspensions using PE-conjugated anti-CD3 (catalogue No. 553064), anti-B220 (catalogue No. 553089), and anti-NK monoclonal antibody (mAb) DX5 (catalogue No. 130-052-501) from BD Biosciences (Heidelberg, Germany) and anti-PE MicroBeads from Miltenyi Biotec (Bergisch-Gladbach, Germany). CD11c ϩ DC were positively selected by MACS MicroBeads from the CD3 Ϫ DX5 Ϫ B220 Ϫ cell population. 22 CD8 T cells were purified from the spleen of OT-I mice using the CD8 T-cell MACS isolation kit (catalogue No. 130-090-859; Miltenyi Biotec).
Flow Cytometry Analysis
Four-color flow cytometry (FCM) analyses were performed as described. 21 
Cell Culture
HC or DC were pulsed for 4 hours with different concentrations of K b -binding OVA 257-264 peptide 23 or the antigenic K b -binding S 208 -215 ILSPFLPL control peptide from hepatitis B virus (HBV). 24 Cells were washed twice, and 1 ϫ 10 5 purified CD8 T cells were cocultured in 200-L flat-bottom microwells with 1 ϫ 10 4 HC or DC/ well. Supernatants were collected from these cocultures at the time points indicated.
Cytokine Determination by Enzyme-Linked Immunosorbent Assay
Cytokines were detected in supernatants by conventional double-sandwich enzyme-linked immunosorbent assay (ELISA 
Thymidine Incorporation Assay
One ϫ 10 5 CD8 T cells/well were cocultured with 1 ϫ 10 4 peptide-pulsed HC or DC in flat-bottom 200 L wells. Cells were pulsed for 6 hours with 1 Ci/well 3 H-thymidine (Amersham Pharmacia Biotech) at day 2 of culture. Thymidine incorporation was measured by liquid scintillation counting. Mean values of triplicate experiments (ϮSEM) are shown.
Results

Surface Phenotype of Primary HC
HC populations were washed, and scatter-gated cells (to exclude doublets) were electronically depleted of CD11b ϩ /CD11c ϩ , MHC class II A bϩ , CD18 ϩ (myeloid and endothelial), CD3 ϩ (T), CD19 ϩ (B), and DX5 ϩ (NK) cells as well as apoptotic (7-AAD ϩ ) cells. No CD11b ϩ / CD11c ϩ , I-A bϩ , CD18 ϩ , CD3 ϩ , CD19 ϩ , and/or DX5 ϩ cells were detectable in these sorted HC populations. Cytologic analyses of isolated HC populations confirmed that Ͼ99% of the isolated cells were viable HC. No MHC-II ϩ CD86 ϩ Ito cells were found that have been recently shown to be potent APC. 25 Primary HC express abundant surface MHC class I (K b and D b ) molecules as previously reported 5 and the integrin intercellular adhesion molecule (ICAM)-1 (CD54) but not ICAM-2 (CD102) (Figure 1 ). No CD18, CD40, or CD70 surface expression was detectable. Of the B7 superfamily molecules, HC expressed only B7-H1 but not CD80, CD86, ICOSL, PD-L2, B7-H3, or B7-H4 ( Figure 1 ). B7-H1 is thus the only candidate costimulator molecule expressed at moderate levels on the HC surface.
Priming Naive CD8 T Cells by HC
Naive (CD3 ϩ CD69 Ϫ CD44 lo CD25 Ϫ ICOS Ϫ ) splenic CD8 T cells from OT-I or RAG1 Ϫ/Ϫ OT-I B6 mice were isolated to Ͼ98% purity ( Figure 2 ). No CD11c ϩ or CD11b ϩ cells were detectable. These naive CD8 T cells expressed the costimulator molecule CD28, the integrin CD18 and its ligands (CD54, CD102), and low levels of the IL-2 receptor ␤-chain (CD122) (Figure 2 ). No surface expression of the coinhibitors CTLA-4 and PD-1 but readily detectable expression of B7-H1 was found. These naive CD8 T cells were cocultured with either professional APC (splenic conventional cDC) or purified HC, both pulsed with titrated doses of antigenic peptide.
The surface phenotype of OT-I CD8 T cells specifically stimulated by peptide-pulsed DC or HC indicated efficient activation of Ͼ96% of the T cells evident by upregulation of CD69; the IL-2 receptor ␣-and ␤-chains (CD25/CD122); the costimulator molecules CD28 and ICOS; and the coinhibitor molecules CTLA-4, PD-1, and B7-H1 (Figure 2A ). No differences were found in the surface phenotype of CD8 T cells primed in vitro by either HC or DC. Although up-regulated PD-1 surface expression was found after a specific 24-hour activation of naive CD8 T cells by HC or DC, up-regulated CD80 surface expression was found only in CD8 T blasts activated for 48 hours ( Figure 2B ). Hence, professional (DC) and nonprofessional (HC) APC prime CD8 T cells equally well. Carboxy-fluorescein-diacetate-succinimidyl ester-labeled, naïve RAG1 Ϫ/Ϫ OT-I CD8 T cells specifically primed by peptidepulsed HC or DC proliferated equally well ( Figure 3A) . Similar proliferative responses were detected when exogenous IL-2 was added or not added to the cocultures (data not shown). OT-I CD8 T cells primed by DC or HC pulsed with titrated amounts of antigenic peptide showed dose-dependent IFN-␥ production that peaked at day 3 of in vitro culture ( Figure 3B and C). IFN-␥ (but not TNF-␣) production by HC-primed CD8 T cells was always higher than that of DC-primed CD8 T cells ( Figure  3B and C), suggesting tighter coinhibitory control of proinflammatory IFN-␥ production by professional APC. TNF-␣ release by HC-primed CD8 T cells was low (in the tested range of 0.1-10 g/mL peptide) ( Figure 3C ). HC thus efficiently prime class I-restricted proliferative and cytokine responses of naive CD8 T cells.
PD-1/B7-H1 Costimulates Priming of CD8 T Cells by HC
B7-H1 is expressed on the surface of HC (Figure 1 ). Surface expression of the B7-H1-binding ligand PD-1 is up-regulated by T cells during activation (Figure 2 ). We tested whether signals derived from these molecules modulate proliferation or cytokine release of OT-I CD8 T cells by titrating increasing amounts of blocking anti-PD-1 and/or anti-B7-H1 antibodies into the T cell/HC (DC) cocultures. IFN-␥ release by CD8 T cells primed by peptide-pulsed HC was down modulated in the presence of either anti-B7-H1 or anti-PD-1 or both antibodies ( Figure 4A ). Similarly, IFN-␥ production of DC-primed OT-I CD8 T cells was down modulated by anti-B7-H1, anti-PD-1, or both antibodies ( Figure 4A ). The moderate down-modulating effect of anti-B7-H1 or anti-PD-1 antibodies on IFN-␥ production in DC-primed CD8 T-cell responses may be due to the fact that DC but not HC express PD-L2 that has a 2-to 6-fold higher affinity to PD-1 than B7-H1. 26 Inhibition of the IFN-␥ response of HC-primed CD8 T cells by anti-B7-H1 and/or anti-PD-1 antibodies showed a clear dose/response relationship, with Ͼ90% suppression apparent at a dose of 50-g antibody/mL ( Figure 4B ). B7-H1 and PD-1 thus facilitate production of IFN-␥ during CD8 T-cell priming by HC.
Substantially higher levels of IL-2 were found in supernatants conditioned by CD8 T cells cocultured with peptide-pulsed HC in the presence of anti-B7-H1 and/or anti-PD-1 antibodies ( Figure 4A ). Higher IL-2 levels in the supernatants of HC-primed CD8 T-cell cultures in the presence of anti-B7-H1 or anti-PD-1 antibodies showed a dose/response relationship with Ͼ5-fold greater amounts of IL-2 being released into the medium at a dose of 25-g antibody/mL ( Figure 4B ). This may result from either inhibition of IL-2 production or enhanced consumption of this growth factor due to greater CD8 T-cell proliferation. Antibody-mediated PD-1 and B7-H1 blockade down modulated clonal expansion of CD8 T cells primed by peptidepulsed HC ( Figure 4C ). This was also observed when exogenous IL-2 was added to the cocultures ( Figure 4C ). Surface expression of the IL-2 receptor ␣-(CD25) and ␤-chain (CD122) by HC-primed CD8 T blasts was similar in the presence of anti-B7-H1 and/or anti-PD-1 antibodies in 5 of 7 experiments ( Figure 4C ) but slightly enhanced in 2 of 7 experiments. CD8 T cells primed by HC in the presence or absence of anti-B7-H1 antibody contained similar amounts of intracellular IL-2 ( Figure 4C ). The anti-B7-H1 antibody down modulated IFN-␥ production by CD8 T cells specifically activated by HC already during the first 24 hours of culture ( Figure 4D) , ie, at time points at which surface expression of CD80 (another counter receptor for B7-H1) was not yet detectable ( Figure 2B ). Enhanced levels of IL-2 in supernatants of cocultures in which CD8 T cells are primed by HC in the presence of blocking anti-PD-1/anti-B7-H1 antibodies thus seem to result from the low consumption of this growth factor by T cells. B7-H1/PD-1-derived signals thus facilitate growth and IFN-␥ production of CD8 T cells primed by HC. 
Naive CD8 T Cells Primed by B7-H1-Deficient HC Display Deficient Proliferative and IFN-␥ Responses
We primed RAG1 Ϫ/Ϫ OT-I CD8 T cells in vitro with B7-H1-deficient HC to confirm the antibody blocking data and to ascertain that B7-H1 expression by presenting HC (and not by responding T cells) is relevant for transmitting the costimulatory signals. Compared with wild-type (wt) HC, congenic B7-H1 Ϫ/Ϫ HC inefficiently stimulated the proliferative response of T cells ( Figure 5A ) and elicited a reduced IFN-␥ response ( Figure 5B ). These data confirm the antibody blocking data. The deficient proliferative response stimulated by B7-H1 Ϫ/Ϫ HC correlated with a late accumulation of IL-2 in the supernatants of these HC/T cell cocultures ( Figure 5 ). There is thus no lack of IL-2 that could explain limited clonal expansion of CD8 T cells stimulated by B7-H1 Ϫ/Ϫ HC. These data support the notion that B7-H1 on the surface of HC facilitates the proliferative and effector cytokine (IFN-␥) responses of naïve CD8 T cells that these nonprofessional APC can prime.
PD-1/B7-H1 Signals Down Modulate Proliferation and IFN-␥ Release of HC-Restimulated CD8 T Blasts
We tested whether the response of effector/memory CD8 T blasts specifically restimulated by HC is costimulated or coinhibited by PD-1/B7-H1 interactions. CD8 T blasts were generated in vitro in 8-day cocultures with peptide-pulsed splenic cDC. IFN-␥ release by OT-I CD8 T blasts in response to specific restimulation by peptide-pulsed HC or DC was up-regulated in the presence of anti-B7-H1 or anti-PD-1 antibodies ( Figure 6A ). This effect of anti-B7-H1 or anti-PD-1 antibodies on the IFN-␥ response of HC-reactivated CD8 T blasts indicates that B7-H1/PD-1-derived signals down-regulate IFN-␥ production in recalled CD8 T-cell responses, ie, support the notion that PD-1/B7-H1 signals induce coinhibition. Only low amounts of IL-2 were found in supernatants of cultures in which CD8 T blasts were restimulated by peptide-pulsed HC, which made testing of the effect of antibody-mediated blockade of B7-H1/PD-1 interactions on the IL-2 response noninformative.
In a second series of experiments, OT-I CD8 T blasts were cocultured with peptide-pulsed, wt, or B7-H1 Ϫ/Ϫ HC, and their proliferation and IFN-␥ release were tested. CD8 T blasts proliferated more vigorously when restimulated by peptide-pulsed, B7-H1-deficient than wt HC ( Figure 6B ). IFN-␥ release by CD8 T blasts specifically restimulated by peptide-pulsed, B7-H1-deficient HC was up-regulated when compared with the response induced by peptide-pulsed, wt HC ( Figure 6B ). B7-H1/PD-1 interaction-derived signals hence down-regulate clonal expansion and IFN-␥ production in recalled CD8 T-cell responses, supporting the antibody blocking data.
Discussion
The present study reveals 2 novel points on CD8 T-cell activation in peripheral tissues. First, the data show that B7-H1 can facilitate specific priming of naive CD8 T cells in situ by nonprofessional APC. Freshly isolated HC that express on the cell surface B7-H1 molecules (but not the costimulator molecules CD40, CD80, CD86, or ICOSL) efficiently primed naive CD8 T cells. This confirms and extends published reports that HC can prime TCR-transgenic CD8 T cells in vitro. 27 B7-H1 on the surface of HC apparently costimulated proliferation and IFN-␥ production of CD8 T cells that they primed. The second point is that the PD-1/B7-H1 interaction inhibited proliferation and IFN-␥ production of CD8 T blasts specifically restimulated by peptide-presenting HC. Depending on their differentiation state, the interaction between the CTLA-4-like PD-1 and the B7-like B7-H1 molecules can thus costimulate or coinhibit proliferation and effector cytokine production of specifically activated CD8 T cells.
A carefully designed protocol was used to purify HC. This involved the in vivo perfusion and collagenase di- 28 Interferons up-regulate surface expression of B7-H1. 29, 30 Cytokines produced early during priming may thus qualify as "third signals" that enhance costimulatory "second signals" of nonprofessional APC, thereby promoting CD8 T-cell priming. CD8 T cells primed by peptide-pulsed HC showed the activated CD69 hi CD28 hi CD44 hi CD62L lo CD45RB lo CD25 hi ICOS hi CTLA-4 hi surface phenotype (Figure 2 ). Although HC express neither the ligands for CD28 and CTLA-4 (CD80 and CD86) nor the ligand for ICOS (ICOSL), surface expression of these homologous molecules was up-regulated by HC-primed CD8 T blasts. Priming by HC and priming by splenic DC generated similar numbers of activated CD8 T blasts with a similar surface phenotype (Figure 2 , data not shown); a similar proliferative response (with or without IL-2 supplements) ( Figure 3A) ; and produced IFN-␥, TNF-␣, and IL-2. The 5-fold higher IFN-␥ production by HC-vs DC-primed CD8 T cells was unexpected. It may point to a more PD-1, a CTLA-4-like molecule PD-1 monomeric in crystal structure analysis, 31 binds B7-H1 and PD-L2 (B7-DC) 8 and is expressed by activated T and B cells. 29 Deficiency of PD-1 in PD-1 Ϫ/Ϫ knockout mice leads to development of autoimmune diseases. 32 Costimulatory PD-1/ PD-L signals that enhance proliferation and cytokine release during T-cell priming have been reported. 26, 33, 34 Interestingly, this was prevalent during CD28-independent T-cell priming. 35 Transgenic mice with B7-H1 ϩ islet ␤ cells spontaneously develop CD8 T-cell-dependent autoimmune diabetes. 36 Site-directed mutagenesis of nonconserved residues of B7-H1 revealed mutants with abolished PD-1 binding that costimulated proliferation and cytokine production of T cells from normal and PD-1-deficient mice. 37 These findings implicate the presence of an independent, costimulatory receptor for B7-H1, whereas the molecular nature of this putative receptor is unknown. Possibly, naive T cells engage B7-H1 on the HC surface with this costimulatory receptor during the first hours of activation when primed T cells do not yet express PD-1. Once PD-1 surface expression is up-regulated (as in effector T cells), the PD-1/B7-H1-derived inhibitory signals may override the effect of the putative costimulatory receptor, and coinhibition would predominate. Alternatively, surface expression of the putative costimulatory receptor may be down-regulated during T-cell activation. Only the molecular identification of a costimulatory receptor of naive T cells for B7-H1 will validate this hypothesis.
Following this line of thought, it may be an oversimplification to postulate a costimulatory B7-H1/PD-1 interaction in this system based on the antibody blocking data. We may face a complex phenomenon. In addition to the putative costimulatory counter receptor on the surface of naive T cells, B7-H1 binds CD80, thereby transmitting an inhibitory signal. 9 It is unclear whether the antibody used blocks the interactions of B7-H1 with both PD-1 and CD80. PD-1 blocking antibody may (1) directly deliver a coinhibitory signal to T cells or (2) indirectly facilitate coinhibition by enhancing the interaction between B7-H1 (on the HC surface) and CD80 (on the T-cell surface). The first possibility is considered unlikely because the anti-PD-1 mAb was used in soluble form in our experiments. Without cross-linking, it is difficult for a mAb to transmit a coinhibitory signal to T cells. The second interpretation is difficult to reconcile with our data obtained with B7-H1-deficient HC. We assume that the interaction of B7-H1 and CD80 plays no role in the "costimulation" because CD80 appears on the T-cell surface late (after PD-1) during activation.
In the liver, the pathway we describe may allow rapid priming of responses of blood-borne CD8 T cells to hepatotropic pathogens in the (peri)sinusoidal compartment. The short time window of 24 -48 hours in which CD8 T cells are specifically trapped in an antigen-bearing liver under experimental conditions 6 indicates that they rapidly traffic from the (peri)sinusoidal to celiac lymph nodes and back into the recirculating pool even if they encounter antigen in the liver. The time frames we used to model priming and restimulation in vitro may therefore be quite realistic. The successful control of many (but not all) hepatotropic viruses by specific CD8 T-cell immunity indicates that the liver supports local priming of specific T-cell immunity. This is supported by the recent demonstration of complete intrahepatic differentiation of CD8 T cells activated within a transplanted liver. 38 To identify which presenting cell in the liver controls local establishment of immunity will require the dissection of individual components of the hepatic immune system in vitro, an approach followed in the present study.
Constitutive or inducible expression of B7-H1 is widespread in normal tissues and tumors. It will be of interest to test whether other tissue cells (eg, intestinal epithelial cells, ␤ cells of the pancreatic islets, or synovial cells of the joints) can use B7-H1 to costimulate in situ priming of specific T-cell responses. This may initiate T-cell responses in peripheral tissues that are subsequently continued in secondary lymphoid tissues. Further in vivo experiments will be required to elucidate the fate of T cells primed by B7-H1/PD-1 costimulation by peripheral, nonprofessional APC.
